drugset / Trial / NCT04514159
A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1b, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-c5 administered orally in combination with abemaciclib (VERZENIO®) in participants with advanced estrogen-receptor positive, human epidermal growth factor receptor-2 negative (ER+/HER2-) breast cancer.
Timeline
- Start
- 2020-11-12
- Primary completion
- 2022-10-24
- Completion
- 2022-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZN-c5 | Unknown | — | Oral |
| Background | Abemaciclib | Small molecule | 150 mg | Oral |